Under the Biden administration, the Department of Justice (DOJ) has reversed course and now backs the constitutionality of the Affordable Care Act (ACA).
The Department of Justice (DOJ) has changed its position on the Supreme Court case involving the severability of the individual mandate from the Affordable Care Act (ACA), now arguing that the ACA should not be struck down if the mandate is deemed unconstitutional.
Under the Trump administration, the DOJ argued the mandate was not severable, but under President Joseph Biden the federal argument is now different. Oral statements were held before the Supreme Court in November 2020 whether the entire ACA should be invalidated. A decision is expected in June.
The Trump administration had sided with Republican-governed states led by Texas that had argued against severability and for the invalidation of the ACA.
The significance for biosimilar markets is that if the ACA is allowed to stand, the biosimilar regulatory approval pathway, or Biologics Price Innovation and Competition Act, which is part of the ACA, will remain also.
The DOJ position was outlined in a letter filed by Deputy Solicitor General Edwin S. Kneedler. “The purpose of this letter is to notify the court that the United States no longer adheres to the conclusions in the previously filed brief of the federal respondents,” Kneedler wrote. “After reconsideration of the issue, it is now the position of the United States that the amended Section 5000A [individual mandate] is constitutional.”
The individual mandate was amended so that individuals do not have to pay a penalty if they do not have coverage for themselves.
Kneedler went on to say that if the Supreme Court decides that the altered section is unconstitutional, it is the DOJ position “that provision is severable from the remainder of the ACA.”
The Biden administration has promised to strengthen Obamacare by improving access to coverage and medical care for residents of the United States.
Treatment Persistence, Safety After Switching to Infliximab Biosimilars in Canadians With IBD
October 5th 2024A retrospective study of a mandatory nonmedical switch in Canada found no significant differences in rates of treatment persistence, loss of response, or adverse events in patients with inflammatory bowel disease (IBD) on maintenance therapy 1 year post-switch.
Eye on Pharma: EC Approved Ustekinumab; Zymfentra Expansion; Biosimilar Policy Briefing
September 26th 2024The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion expanded access to Zymfentra (subcutaneous infliximab-dyyb) through partnerships with Cigna and Express Scripts, and the Association for Accessible Medicines held a policy briefing addressing barriers to biosimilar adoption.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
French Study Finds High Patient Satisfaction With Adalimumab Biosimilar Treatment for IBD
September 21st 2024An observational study assessing patient satisfaction with adalimumab for inflammatory bowel disease (IBD) reported a high level of satisfaction with all adalimumab product, including biosimilars.